Milestone Scientific Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved all proposals, including director elections, increased authorized shares, and expanded the equity incentive plan. Leadership emphasized operational discipline, growth, and alignment of executive incentives with performance milestones.
-
Revenue and gross profit remained stable, with significant cost reductions narrowing net loss by 58%. Medical segment revenue more than doubled, driven by CompuFlo adoption and digital marketing, while new financing supports growth and international expansion.
Fiscal Year 2025
-
Disciplined restructuring and targeted growth initiatives led to improved operating results in 2025, with double-digit revenue growth and significant CompuFlo expansion expected in 2026. Cash flow break even is targeted for early 2027.
-
Q3 2025 saw stable revenues and gross profit, with operating expenses reduced by over $500,000 year-over-year. Dental remains the main revenue driver, while medical segment progress hinges on Medicare reimbursement and focused commercialization. Cash position supports operations for several quarters.
-
Q2 2025 revenue rose 25% year-over-year to $2.3M, led by international dental sales, while operating loss narrowed. Medicare reimbursement progress and new leadership set the stage for focused growth in both dental and medical segments.
Fiscal Year 2024
-
Q3 2024 revenue grew 22% year-over-year to $2.5M, led by strong dental and medical segment advances, including Medicare reimbursement for CompuFlo and international expansion. Gross margins remained high, and net loss improved due to operational gains and a $2M tax asset sale.
-
Medicare reimbursement approval and a new distributor partnership have accelerated commercialization, with a focus on building recurring revenue in pain management clinics. The technology offers significant clinical and economic benefits, while the dental business remains profitable and international expansion is underway.
-
A high-margin, debt-free company leverages proprietary injection technology to expand from a profitable dental legacy into the $2 billion U.S. epidural market, supported by strong clinical validation, recent Medicare reimbursement wins, and strategic partnerships for disciplined commercial rollout.
-
Medicare reimbursement for CompuFlo and a new partnership with Axial Biologics mark a pivotal commercial milestone, while U.S. e-commerce dental sales and gross margins improved. Despite lower international sales, the company posted a Q2 net profit and maintains a strong balance sheet.